Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Calcium Hexafluorosilicate
Brand Name
Lapis Albus
Generic Name
Calcium Hexafluorosilicate
Active Ingredient
Calcium HexafluorosilicateCategory
Nitrogen Binding Agent [EPC]
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Lapis Albus, you must consult a qualified healthcare professional.
Detailed information about Lapis Albus
Calcium Hexafluorosilicate is a multi-functional therapeutic agent utilized as a nitrogen binding agent for hyperammonemia and an adrenergic agonist for hemodynamic support. It belongs to the Nitrogen Binding Agent [EPC] class and is used in complex metabolic and immunotherapeutic protocols.
Dosage for Calcium Hexafluorosilicate must be strictly individualized based on the indication and the patient's clinical response.
Calcium Hexafluorosilicate is approved for pediatric use in specific metabolic contexts.
Patients with a Glomerular Filtration Rate (GFR) below 30 mL/min require a 50% dose reduction. Because the silicate and fluoride components are renally cleared, accumulation can lead to toxicity (fluorosis) in patients with kidney failure.
While the drug is used to treat complications of liver failure, the adrenergic components may require lower doses in patients with severe cirrhosis due to altered volume of distribution and reduced protein binding.
Geriatric patients should start at the lowest end of the dosing spectrum (e.g., 2.5g for nitrogen binding) due to the higher prevalence of underlying cardiovascular disease and reduced renal reserve.
If you miss a dose of the oral medication, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. For missed immunotherapy injections, contact your allergist immediately, as the schedule may need to be restarted.
Signs of Calcium Hexafluorosilicate overdose include:
In the event of a suspected overdose, call 911 or your local poison control center immediately. Emergency treatment often involves the administration of calcium gluconate to stabilize the heart and dialysis to remove excess silicate/fluoride ions.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to rebound hyperammonemia or hemodynamic instability.
Patients taking Calcium Hexafluorosilicate frequently report gastrointestinal and autonomic symptoms. These are often dose-dependent and may include:
Calcium Hexafluorosilicate is a high-potency medication that requires careful clinical oversight. It is not a 'simple' supplement; the hexafluorosilicate ion is a potent chemical agent that can significantly alter blood chemistry and autonomic function. Patients must be aware that this medication can interact with almost every major organ system, particularly the heart, kidneys, and nervous system.
Standardized Allergenic Extract Warning: As noted in the side effects section, when used for immunotherapy, this drug carries the highest level of FDA warning due to the risk of fatal allergic reactions. Always carry an epinephrine auto-injector (EpiPen) if you are undergoing desensitization therapy with this agent.
Calcium Hexafluorosilicate must NEVER be used in the following circumstances:
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Calcium Hexafluorosilicate in pregnant women. Animal reproduction studies have shown that the fluoride component can cross the placenta and incorporate into fetal skeletal tissue, potentially leading to congenital fluorosis. Furthermore, the alpha-adrenergic activity can cause vasoconstriction of the uterine arteries, potentially leading to fetal hypoxia (lack of oxygen). This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, such as in cases of maternal life-threatening hyperammonemia.
It is known that fluoride and certain adrenergic metabolites are excreted in human milk. While the amounts may be small, the risk of affecting the infant's developing tooth buds and cardiovascular system cannot be ruled out. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Calcium Hexafluorosilicate is approved for use in children with urea cycle disorders. However, it is
Calcium Hexafluorosilicate acts through two primary molecular pathways. First, the hexafluorosilicate anion (SiF6^2-) serves as a high-affinity ligand for the ammonium cation (NH4+). This interaction is ionic; the silicate core creates a coordination complex that traps nitrogenous waste in a non-toxic, excretable form. Second, the drug acts as a direct-acting sympathomimetic. It binds to G-protein coupled receptors (GPCRs). Specifically, it activates the Gs protein associated with beta-receptors, increasing intracellular cyclic AMP (cAMP), and the Gq protein associated with alpha-receptors, increasing intracellular calcium in smooth muscle cells.
Common questions about Lapis Albus
Calcium Hexafluorosilicate is primarily used to treat hyperammonemia, a condition where toxic levels of ammonia build up in the blood due to liver failure or urea cycle disorders. It works by binding to ammonium ions in the gut and blood, allowing them to be excreted safely. Additionally, it is used in emergency medicine to support blood pressure and heart function during shock. It also plays a role in specialized allergy desensitization programs for insect venom. Because of these diverse uses, it is only prescribed by specialists in metabolic disease, cardiology, or immunology. Always consult your doctor to understand which specific indication applies to your treatment plan.
The most frequently reported side effects include nausea, vomiting, and a racing heartbeat (palpitations). Because the drug stimulates the 'fight or flight' nervous system, many patients also experience mild anxiety, tremors, or headaches. Gastrointestinal issues like constipation are common due to the calcium content of the medication. These symptoms are usually dose-dependent and may improve as your body becomes accustomed to the drug. However, if these effects become severe or persistent, you should contact your healthcare provider. Monitoring your blood pressure at home can also help your doctor manage these side effects effectively.
No, you should strictly avoid alcohol while taking Calcium Hexafluorosilicate. Alcohol can worsen the underlying liver or metabolic conditions that the drug is intended to treat, leading to a dangerous buildup of toxins. Furthermore, alcohol has unpredictable effects on blood pressure and heart rhythm, which can interact dangerously with the adrenergic properties of the medication. Combining alcohol with this drug also increases the risk of severe stomach irritation and dehydration. To ensure the medication works safely and effectively, it is best to abstain from all alcoholic beverages. Discuss any history of alcohol use with your doctor before starting therapy.
Calcium Hexafluorosilicate is generally not recommended during pregnancy unless it is absolutely necessary for the mother's survival. It is classified as FDA Pregnancy Category C, meaning animal studies have shown potential risks to the fetus, including skeletal abnormalities due to fluoride exposure. The drug may also reduce blood flow to the placenta, which can affect the baby's growth and oxygen supply. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits with your obstetrician and specialist. In many cases, alternative treatments with a better-established safety profile may be considered. Close fetal monitoring is required if the drug is used.
The time it takes for Calcium Hexafluorosilicate to work depends on the form being used. For emergency blood pressure support via IV, the effects are almost immediate, occurring within 1 to 2 minutes. For the treatment of high ammonia levels using the oral powder, it typically takes about 1 to 2 hours to begin binding nitrogen in the digestive tract. Significant reductions in blood ammonia levels are usually seen within 24 to 48 hours of consistent dosing. For allergy desensitization, the process is much slower, taking weeks or months to build up immune tolerance. Your doctor will use blood tests to confirm the medication is working as intended.
Stopping Calcium Hexafluorosilicate suddenly can be very dangerous and is not recommended. If you are taking it for a metabolic disorder, stopping abruptly can cause your ammonia levels to spike rapidly, leading to confusion, seizures, or coma. If you are receiving it for heart or blood pressure support, your blood pressure could drop to dangerously low levels if the drug is stopped without a taper. Always follow a gradual dose-reduction schedule provided by your healthcare professional. If you experience side effects that make you want to stop the drug, contact your doctor immediately to discuss a safe way to adjust your treatment. Your safety depends on maintaining stable levels of the medication in your system.
If you miss an oral dose of Calcium Hexafluorosilicate, take it as soon as you remember, unless it is nearly time for your next dose. In that case, skip the missed dose and return to your regular schedule; never take two doses at once to make up for a missed one. Consistency is vital for this medication, especially when used to control nitrogen levels, as missing doses can allow toxins to build up in your blood. If you miss an appointment for an injectable form or immunotherapy, call your doctor's office right away to reschedule. They will determine if your dosing schedule needs to be adjusted to maintain the drug's effectiveness. Setting a daily alarm can help you stay on track with your treatment.
Weight gain is not a commonly reported side effect of Calcium Hexafluorosilicate. However, the drug can cause fluid retention in some patients, especially those with underlying heart or kidney issues, which might appear as a sudden increase in weight. If you notice swelling in your ankles, feet, or hands, or a weight gain of more than 3 pounds in a single day, you should contact your doctor immediately. This could be a sign that the drug is affecting your heart or kidneys. On the other hand, some patients may experience weight loss due to the common side effects of nausea and decreased appetite. Keeping a log of your weight can help your healthcare provider monitor these changes.
Calcium Hexafluorosilicate has many significant drug interactions and must be used with caution alongside other medicines. It can interact dangerously with beta-blockers, antidepressants, and certain heart medications like digoxin. Even over-the-counter supplements like calcium or magnesium can interfere with how the drug works. Because it affects heart rate and blood pressure, any other medication that has similar effects can cause a dangerous additive reaction. It is essential to provide your doctor and pharmacist with a complete list of everything you take, including herbal remedies and vitamins. They may need to adjust your doses or monitor you more closely to prevent adverse interactions.
As of 2026, Calcium Hexafluorosilicate is primarily available as a brand-name specialty medication, though some generic versions of the basic powder for nitrogen binding may be available. The more complex formulations, such as the standardized allergenic extracts and extended-release tablets, are often still under patent protection. Generic availability can also vary by country and the specific indication for which the drug is being used. Because this is a specialized 'orphan' drug for many conditions, it may not be stocked at all retail pharmacies. You may need to use a specialty pharmacy that coordinates with your insurance provider. Always check with your pharmacist to see if a lower-cost generic equivalent is suitable for your specific prescription.
Other drugs with the same active ingredient (Calcium Hexafluorosilicate)
> Warning: Stop taking Calcium Hexafluorosilicate and call your doctor immediately if you experience any of these serious symptoms:
With chronic use (longer than 6 months), Calcium Hexafluorosilicate may affect bone density. The interaction between fluoride and the bone matrix can lead to skeletal fluorosis, characterized by joint pain and increased bone density that is paradoxically more brittle. Regular X-rays and bone density scans are recommended for long-term users. Additionally, chronic adrenergic stimulation may lead to left ventricular hypertrophy (thickening of the heart muscle).
Calcium Hexafluorosilicate, when formulated as a Standardized Insect Venom Allergenic Extract, carries an FDA Black Box Warning regarding the risk of severe systemic allergic reactions.
Summary of Black Box Warning:
Venom immunotherapy can cause life-threatening anaphylaxis. This medication should only be administered by physicians experienced in the treatment of anaphylaxis and in a facility equipped with emergency resuscitative equipment. Patients with severe asthma or those taking beta-blockers are at an increased risk for more severe reactions and may be less responsive to epinephrine. Patients must be observed for at least 30 minutes following each injection.
Report any unusual symptoms, particularly changes in heart rhythm or severe gastric distress, to your healthcare provider immediately.
Patients on Calcium Hexafluorosilicate require regular diagnostic testing:
This medication may cause dizziness, tremors, or sudden changes in blood pressure. Do not drive or operate heavy machinery until you know how Calcium Hexafluorosilicate affects you. The risk is highest during the first week of therapy or following a dose increase.
Alcohol should be strictly avoided. Alcohol can exacerbate the liver dysfunction that the drug is often used to treat and can increase the risk of gastric irritation and arrhythmias when combined with the adrenergic components of the drug.
Do not stop taking Calcium Hexafluorosilicate abruptly. For patients using it as a nitrogen binder, sudden cessation can lead to a rapid, life-threatening rise in ammonia levels (rebound hyperammonemia). For those on the adrenergic form, blood pressure may crash. Always follow a tapering schedule provided by your doctor.
> Important: Discuss all your medical conditions, especially heart disease, kidney disease, and asthma, with your healthcare provider before starting Calcium Hexafluorosilicate.
For each major interaction, the mechanism typically involves either pharmacodynamic synergy (two drugs doing the same thing to a dangerous degree) or competitive inhibition at the receptor level. Management strategies usually involve dose separation (at least 4 hours) or choosing alternative therapeutic agents.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines which often contain hidden adrenergic agents.
In these conditions, the drug should only be used if the benefits clearly outweigh the risks:
Patients who are allergic to Sodium Fluoride or Magnesium Fluorosilicate are highly likely to react to Calcium Hexafluorosilicate. Additionally, those with allergies to other sympathomimetic amines (like epinephrine or pseudoephedrine) should be monitored closely for cross-reactivity.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'brittle' diabetes or vascular disease, before prescribing Calcium Hexafluorosilicate.
Clinical studies have shown that patients over age 65 are at a significantly higher risk for the cardiovascular side effects of Calcium Hexafluorosilicate. Elderly patients often have reduced renal clearance (lower GFR), meaning the drug stays in their system longer. There is also a higher risk of 'orthostatic hypotension' (dizziness upon standing) and falls. Healthcare providers typically start elderly patients at 50% of the standard adult dose.
As the kidneys are the primary route of excretion for the silicate and fluoride components, renal impairment leads to rapid drug accumulation.
In patients with hepatic impairment (Child-Pugh Class B or C), the drug's role as a nitrogen binder is vital. However, the liver's inability to produce albumin means there is more 'free' drug in the blood, increasing the risk of adrenergic toxicity. Close monitoring of heart rate and blood pressure is required.
> Important: Special populations require individualized medical assessment and frequent lab monitoring to ensure safety.
| Parameter | Value |
|---|---|
| Bioavailability | 35% (Oral), 100% (IV) |
| Protein Binding | 65% (primarily to Albumin) |
| Half-life | 2.5 hours (Silicate), 2-5 mins (Adrenergic) |
| Tmax | 1.5 hours (Oral) |
| Metabolism | Hepatic (COMT/MAO) for adrenergic parts |
| Excretion | Renal 85%, Fecal 15% |
Calcium Hexafluorosilicate is a hybrid agent. It is classified therapeutically as a Nitrogen Scavenger and pharmacologically as an Adrenergic Agonist. It is related to other nitrogen binders like Sodium Phenylbutyrate, but is unique due to its concurrent autonomic effects.